QuickView: Iluvien set for growth in 2015
Net revenue increased 89% to $3.9m in Q115 as in late February; Alimerabegan US sales of its lead product, Iluvien. The intraocular steroid implant
is FDA approved for diabetic macular edema (DME). Iluvien has a duration
of three years, giving it an advantage over other intraocular injections for
DME. With a market of 21m patients worldwide with DME, Iluvien revenues
could dramatically increase this year.
Alimera Sciences is a pharmaceutical company that is engaged in the commercialization and development of prescription ophthalmic pharmaceuticals. The company's commercial product is ILUVIEN?, an intravitreal implant that treats patients by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. ILUVIEN was initially developed to treat diabetic macular edema, a disease of the retina that affects individuals with diabetes and can lead to vision loss and blindness. The company commercially markets ILUVIEN in the United States, Germany, the United Kingdom, Portugal, Austria and Ireland. The company has three segments: the United States, International and Other.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.